Motif Bio Plc (MTFB):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Motif Bio Plc (MTFB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9366
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:55
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Motif Bio Plc (Motif Bio), formerly Motif Bio Ltd, is a clinical-stage biopharmaceutical company that focuses on the development of novel antibiotics to treat patients with infections caused by multi-drug resistant bacteria. The company develops Iclaprim, a targeted Gram-positive1 antibiotic with activity against methicillin-resistant Staphylococcus aureus. Its indications for iclaprim include hospital-acquired bacterial pneumonia (HABP) including ventilator-associated bacterial pneumonia (VABP) and Staphylococcus aureus lung infections in people with cystic fibrosis. The company has operations in the UK and the US. Motif Bio is headquartered in London, the UK.

Motif Bio Plc (MTFB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Motif Bio Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Motif Bio Plc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Motif Bio Enters into Agreement with Covance 11
Motif BioSciences Enters Into Co-Development Agreement With Jubilant Biosys 12
Merger 13
Motif Biosciences to Merge with Pharmaceutical Company 13
Equity Offering 14
Motif Bio Raises USD13.5 Million in Private Placement of Shares 14
Motif Bio Raises Funds through Private Placement of Shares up on Exercise of Warrants 15
Motif Bio Raises Funds through Private Placement of Shares up on Exercise of Warrants 16
Motif Bio Files Registration Statement to Raise up to USD80 Million in Public Offering of Securities 17
Motif Bio Files Registration Statement to Raise Funds through Private Placement of ADS upon Exercise of Warrants 18
Motif Bio to Raise USD0.1 Million in Public Offering of Shares up on Exercise of Warrants 19
Motif Bio to Raise USD25 million in Placing of New Ordinary Shares 20
Motif Bio Raises Funds through Private Placement of Shares and Warrants 21
Motif Bio Raises USD17 Million in Public Offering of American Depositary Shares and Warrants 23
Motif Bio Raises Funds through Private Placement upon Exercise of Warrants 25
Motif Bio Raises Funds in Private Placement upon Exercise of Warrants 26
Motif Bio Raises USD35 Million in Private Placement of Shares 27
Motif Bio Raises USD41.8 Million in IPO 28
Debt Offering 29
Motif Bio to Raise USD20 Million in Private Placement of Debt Financing 29
Acquisition 30
Motif BioSciences Acquires Nuprim 30
Motif Bio Plc – Key Competitors 31
Motif Bio Plc – Key Employees 32
Motif Bio Plc – Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Recent Developments 34
Financial Announcements 34
Sep 25, 2018: Motif Bio announces Half-Year 2018 financial results and operational progress 34
Apr 10, 2018: Motif Bio Reports Fiscal Year 2017 Results 35
Sep 29, 2017: Motif Bio reports half-year 2017 financial results and operational progress 39
May 01, 2017: Motif Bio Reports Year-End 2016 Financial Results 40
May 01, 2017: Motif Bio annual net loss up 41
Corporate Communications 42
Jul 03, 2018: Motif Bio Announces Resignation of Robert Bertoldi from Board of Directors 42
Feb 02, 2018: Motif Bio Appoints Jonathan E. Gold As Interim Chief Financial Officer 43
May 10, 2017: Motif Bio Appoints Scientific Opinion Leaders to Advisory Board 44
May 05, 2017: Motif Bio Appoints Dr. Craig Albanese as Non-Executive Director 45
Jan 17, 2017: Motif Bio: Appointment of Chief Financial Officer 46
Government and Public Interest 47
Jan 29, 2018: Motif Bio, Spero Therapeutics and Vical Join Antimicrobials Working Group 47
Product News 48
06/22/2017: Motif Bio Invited to Present at Infectious Diseases Conference 48
Clinical Trials 49
Aug 09, 2017: Motif Bio’s second Phase 3 clinical trial in ABSSSI finishes patient treatment phase 49
Jul 06, 2017: Motif Bio to Present Three Posters at IDWeek 2017 50
May 01, 2017: Motif Bio Reports Year-end 2016 Financial Results 51
Apr 18, 2017: Motif Bio Announces Positive Results For Iclaprim, In The Revive-1 Phase 3 Study 52
Jan 30, 2017: Motif Bio Phase 3 Clinical Trial Finishes Patient Treatment Phase 53
Other Significant Developments 54
Mar 13, 2018: Motif Bio: Change of Registered Office 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55

List of Tables
Motif Bio Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Motif Bio Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Motif Bio Plc, Deals By Therapy Area, 2012 to YTD 2018 9
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Motif Bio Enters into Agreement with Covance 11
Motif BioSciences Enters Into Co-Development Agreement With Jubilant Biosys 12
Motif Biosciences to Merge with Pharmaceutical Company 13
Motif Bio Raises USD13.5 Million in Private Placement of Shares 14
Motif Bio Raises Funds through Private Placement of Shares up on Exercise of Warrants 15
Motif Bio Raises Funds through Private Placement of Shares up on Exercise of Warrants 16
Motif Bio Files Registration Statement to Raise up to USD80 Million in Public Offering of Securities 17
Motif Bio Files Registration Statement to Raise Funds through Private Placement of ADS upon Exercise of Warrants 18
Motif Bio to Raise USD0.1 Million in Public Offering of Shares up on Exercise of Warrants 19
Motif Bio to Raise USD25 million in Placing of New Ordinary Shares 20
Motif Bio Raises Funds through Private Placement of Shares and Warrants 21
Motif Bio Raises USD17 Million in Public Offering of American Depositary Shares and Warrants 23
Motif Bio Raises Funds through Private Placement upon Exercise of Warrants 25
Motif Bio Raises Funds in Private Placement upon Exercise of Warrants 26
Motif Bio Raises USD35 Million in Private Placement of Shares 27
Motif Bio Raises USD41.8 Million in IPO 28
Motif Bio to Raise USD20 Million in Private Placement of Debt Financing 29
Motif BioSciences Acquires Nuprim 30
Motif Bio Plc, Key Competitors 31
Motif Bio Plc, Key Employees 32
Motif Bio Plc, Subsidiaries 33

List of Figures
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Motif Bio Plc (MTFB):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Jordan French Insurance Co. (P.L.C.):企業の戦略・SWOT・財務情報
    Jordan French Insurance Co. (P.L.C.) - Strategy, SWOT and Corporate Finance Report Summary Jordan French Insurance Co. (P.L.C.) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Ambu AS (AMBU B):企業の財務・戦略的SWOT分析
    Ambu AS (AMBU B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Control4 Corporation (CTRL)-エネルギー分野:企業M&A・提携分析
    Summary Control4 Corporation (Control4) is a provider of automation systems and control solutions for homes and businesses. It focuses on smart lighting, networking solutions and safety and security solutions. The company offers personalized control solutions for lighting, video, music, energy and s …
  • Southern California Gas Co:企業の戦略的SWOT分析
    Southern California Gas Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Yuanta Financial Holding Co., Ltd.:企業の戦略・SWOT・財務情報
    Yuanta Financial Holding Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Yuanta Financial Holding Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Wuhan Kaidi Electric Power Co Ltd (000939):電力:M&Aディール及び事業提携情報
    Summary Wuhan Kaidi Electric Power Co Ltd (Wuhan Kaidi) is a renewable energy company that offers power supply and new energies technology and services. The company produces biomass energy from forestry and agricultural residues. Its services include technical research and development, investment an …
  • Green Plains Inc.:企業の戦略・SWOT・財務情報
    Green Plains Inc. - Strategy, SWOT and Corporate Finance Report Summary Green Plains Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Ternium SA:戦略・SWOT・企業財務分析
    Ternium SA - Strategy, SWOT and Corporate Finance Report Summary Ternium SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Damac Real Estate Development Ltd
    Damac Real Estate Development Ltd - Strategy, SWOT and Corporate Finance Report Summary Damac Real Estate Development Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Klaria Pharma Holding AB (KLAR):製薬・医療:M&Aディール及び事業提携情報
    Summary Klaria Pharma Holding AB (Klaria Pharma) is a developer of fast acting medicinal products that designes, develops and commercializ therapeutics for migraine and cancer related pain. The company’s patented drug delivery platform is an alginate-based polymer film, facilitates quick and dependa …
  • H.I.G. Capital LLC:企業の戦略的SWOT分析
    H.I.G. Capital LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Fidelity Bank Plc:企業の戦略・SWOT・財務情報
    Fidelity Bank Plc - Strategy, SWOT and Corporate Finance Report Summary Fidelity Bank Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Marksmen Energy Inc (MAH):石油・ガス:M&Aディール及び事業提携情報
    Summary Marksmen Energy Inc (Marksmen Energy), formerly Marksmen Resources Ltd is an oil and gas exploration and development company that explores and develops light oil assets in Ohio. The company acquires, explores, operates, mines, manages, produces and develops oil and gas properties in Western …
  • Pfizer Inc.:企業のM&A・事業提携・投資動向
    Pfizer Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Pfizer Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • Sorrento Therapeutics Inc (SRNE):製薬・医療:M&Aディール及び事業提携情報
    Summary Sorrento Therapeutics Inc (STI), formerly QuikByte Software Inc, is a cancer therapeutic service provider. The company offers CD38 CAR-T, lidocaine topical system, resiniferatoxin. Its product pipeline includes CD38 CAR-T, CEA CAR-T, CD38 ADC and seprehvir. STI provides treatment for multipl …
  • Glen Dimplex Group:企業の戦略的SWOT分析
    Glen Dimplex Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Bank Gutmann AG:企業の戦略・SWOT・財務情報
    Bank Gutmann AG - Strategy, SWOT and Corporate Finance Report Summary Bank Gutmann AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • PT Central Proteina Prima Tbk (CPRO):企業の財務・戦略的SWOT分析
    PT Central Proteina Prima Tbk (CPRO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Magnora ASA (SEVAN):企業の財務・戦略的SWOT分析
    Summary Magnora ASA (Magnora) is an oil and gas company that offers engineering, design, and project execution of floating units for offshore applications. The company's floating production units include Hummingbird spirit, Voyageur spirit, Piranema spirit, Goliat FPSO and Western Isles FPSO, among …
  • Inotek Pharmaceuticals Corp (RCKT):製薬・医療:M&Aディール及び事業提携情報
    Summary Inotek Pharmaceuticals Corp (IPC) is a clinical-stage biopharmaceutical company that focus on the discovery and development of novel therapeutics for the treatment of glaucoma and serious diseases of the eye. The company’s trabodenoson is a selective adenosine mimetic that stimulates a speci …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆